Takeda
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).
Takeda: 408 sponsored US clinical trials, 49 recruiting.
Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.
Top-decile sponsor footprint
Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
408 total, page 7 of 9
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
NCT00942175
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
NCT01023581
Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults
NCT00914862
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
NCT00957268
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
NCT00968708
Norwalk Vaccine Study
NCT00973284
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
NCT00790933
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
NCT00890448
Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
NCT00847210
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00846365
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
NCT00856284
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00818883
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
NCT00847808
Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension
NCT00847626
Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
NCT00752791
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
NCT00752609
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus
NCT00722917
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00731120
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00734071
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
NCT00707993
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT00707980
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
NCT00730691
Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
NCT00708175
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
NCT00672958
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
NCT00672620
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
NCT00696436
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
NCT00677053
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
NCT00627016
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
NCT00629876
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
NCT00591578
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
NCT00591266
Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome
NCT00593736
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
NCT00591253
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
NCT00641732
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
NCT00591773
Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia
NCT00865228
Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia
NCT00532311
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
NCT00727857
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696384
Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00696241
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
NCT00695955
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
NCT00653185
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
NCT00471094
Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
NCT00492232
MPC-004 for the Treatment of an Acute Gout Flare
NCT00506883
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
NCT00760344
Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers
NCT00492011
Efficacy and Safety of Oral Febuxostat in Participants With Gout
NCT00430248
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
NCT00432276
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
NCT00395512
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 90 |
| Phase 3 | 148 |
| Phase 4 | 26 |
What is open in the Takeda pipeline
49 recruiting of 408 indexed (12% open); 284 completed (70%).
Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).
Top condition: Healthy Volunteers (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Takeda: open-pipeline peers nationwide
Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 408 trials (± recruiting share)
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Arcus Biosciences · 12% recruiting · 25 trials
- Ardelyx · 12% recruiting · 25 trials
- Kyowa Kirin Co. · 12% recruiting · 25 trials
- East Carolina University · 12% recruiting · 58 trials
Related
What to do with this Takeda page
408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.
- 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.